Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol

Chemoradiotherapy with cisplatin in a triweekly regimen of 100 mg/m2 body surface area, is used to treat locally advanced head and neck squamous cell carcinoma (HNSCC) with curative intent. Cisplatin dose limiting toxicity (CDLT) occurs often and impedes obtaining the planned cumulative cisplatin do...

Descripción completa

Detalles Bibliográficos
Autores principales: Schaeffers, Anouk W. M. A., Devriese, Lot A., van Gils, Carla H., Dankbaar, Jan Willem, Voortman, Jens, de Boer, Jan Paul, Slingerland, Marije, Hendriks, Mathijs P., Smid, Ernst J., Frederix, Geert W. J., de Bree, Remco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681175/
https://www.ncbi.nlm.nih.gov/pubmed/38011186
http://dx.doi.org/10.1371/journal.pone.0294147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681175/
https://www.ncbi.nlm.nih.gov/pubmed/38011186
http://dx.doi.org/10.1371/journal.pone.0294147

Ejemplares similares